Geron Corp (GERN) 2.01 $GERN
Geron Announces Record Date for Distribution of Asterias Series A Common Stock
Thomson Reuters ONE - Fri May 09, 6:30AM CDT
Menlo Park, CA, May 9, 2014 - Geron Corporation (Nasdaq: GERN) today announced that it has set May 28, 2014 as the record date for the distribution to Geron stockholders of the Series A Common Stock from Asterias Biotherapeutics, Inc. ("Asterias"
that Geron received in the previously announced transaction to divest Geron's human embryonic stem cell assets, which closed on October 1, 2013. Geron expects to complete by the end of July 2014 the distribution of the 6,537,779 shares of Asterias Series A common stock, to be made on a pro rata basis to eligible Geron stockholders of record as of the close of business on the record date.
EQUITY ALERT: Rosen Law Firm Reminds Geron Corporation Investors of Important May 13, 2014, Class Action Deadline -- GERN
GlobeNewswire - Thu May 08, 8:26PM CDT
The Rosen Law Firm, P.A. reminds all purchasers of the common stock of Geron Corporation (Nasdaq:GERN) from June 16, 2013 through March 11, 2014, of the important May 13, 2014 lead plaintiff deadline in the class action.
Geron to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Thomson Reuters ONE - Wed May 07, 10:15PM CDT
MENLO PARK, Calif., May 7, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV. The presentation is scheduled to occur on Thursday, May 15th at 12:40 p.m. Pacific Time.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against GERON CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- GERN
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Geron Corporation ("Geron" or the "Company" (Nasdaq:GERN) common stock between June 16, 2013 to March 11, 2014.
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Geron Corporation ("Geron" or the "Company" (NASDAQ:GERN) that all purchasers of Geron securities between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Geron Reports In-Line Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 8:50AM CDT
Geron (GERN) is working on gathering data required by the FDA to lift the clinical hold on imetelstat.
Geron Corporation Reports First Quarter 2014 Financial Results
Thomson Reuters ONE - Thu May 01, 3:06PM CDT
Conference Call Scheduled for 4:30 p.m. EDT Today, May 1st
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Geron Corporation and Certain Officers - GERN
PR Newswire - Fri Apr 25, 4:27PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company" (NASDAQ: GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
Lieff Cabraser Reminds Geron Corporation Investors of Upcoming Deadline in Class Action Litigation - GERN
Business Wire - Thu Apr 24, 8:01AM CDT
Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 13, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired the securities of Geron Corporation ("Geron" or the "Company" (NasdaqGS: GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" .
Geron Announces Conference Call to Discuss First Quarter 2014 Financial Results
Thomson Reuters ONE - Wed Apr 23, 3:21PM CDT
Menlo Park, Calif., April 23, 2014 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the first quarter ended March 31, 2014, on Thursday, May 1, 2014, after the market close. Geron's management will also host a conference call for analysts and investors on Thursday, May 1, 2014, at 4:30 p.m. Eastern Time to discuss the company's first quarter results and recent events.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Apr 23, 6:45AM CDT
Keep these under-$10 biotech stocks on your trading radar.
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:45PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline -- GERN
GlobeNewswire - Fri Apr 11, 3:12PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company" (Nasdaq:GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Geron Corporation ("Geron" or the "Company" (NASDAQ:GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Hagens Berman Reminds Investors of May 13, 2014, Lead Plaintiff Deadline in Geron Securities Class Action
Business Wire - Wed Apr 09, 12:38PM CDT
Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company" for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the May 13, 2014 lead plaintiff deadline. Investors who have suffered significant financial losses, and who want to discuss their options, can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing Geron@hbsslaw.com or by calling 510-725-3000.
Geron Announces Record Date for Distribution of Asterias Series A Common Stock
Thomson Reuters ONE - Fri May 09, 6:30AM CDT
Menlo Park, CA, May 9, 2014 - Geron Corporation (Nasdaq: GERN) today announced that it has set May 28, 2014 as the record date for the distribution to Geron stockholders of the Series A Common Stock from Asterias Biotherapeutics, Inc. ("Asterias"
that Geron received in the previously announced transaction to divest Geron's human embryonic stem cell assets, which closed on October 1, 2013. Geron expects to complete by the end of July 2014 the distribution of the 6,537,779 shares of Asterias Series A common stock, to be made on a pro rata basis to eligible Geron stockholders of record as of the close of business on the record date. EQUITY ALERT: Rosen Law Firm Reminds Geron Corporation Investors of Important May 13, 2014, Class Action Deadline -- GERN
GlobeNewswire - Thu May 08, 8:26PM CDT
The Rosen Law Firm, P.A. reminds all purchasers of the common stock of Geron Corporation (Nasdaq:GERN) from June 16, 2013 through March 11, 2014, of the important May 13, 2014 lead plaintiff deadline in the class action.
Geron to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Thomson Reuters ONE - Wed May 07, 10:15PM CDT
MENLO PARK, Calif., May 7, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV. The presentation is scheduled to occur on Thursday, May 15th at 12:40 p.m. Pacific Time.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against GERON CORPORATION and Its Board of Directors and a Lead Plaintiff Deadline of May 13, 2014 -- GERN
GlobeNewswire - Tue May 06, 12:02PM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of investors who purchased Geron Corporation ("Geron" or the "Company"
(Nasdaq:GERN) common stock between June 16, 2013 to March 11, 2014. INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors Of The Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Tue May 06, 9:32AM CDT
Glancy Binkow & Goldberg LLP reminds investors of Geron Corporation ("Geron" or the "Company"
(NASDAQ:GERN) that all purchasers of Geron securities between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Geron Reports In-Line Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 8:50AM CDT
Geron (GERN) is working on gathering data required by the FDA to lift the clinical hold on imetelstat.
Geron Corporation Reports First Quarter 2014 Financial Results
Thomson Reuters ONE - Thu May 01, 3:06PM CDT
Conference Call Scheduled for 4:30 p.m. EDT Today, May 1st
Why You Should Watch Exelixis Inc., Geron Corporation and Vertex Pharmaceuticals Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:01AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exelixis , Geron , and Vertex Pharmaceuticals today. Exelixis set to release first quarter results today Normally, earnings season for...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Geron Corporation and Certain Officers - GERN
PR Newswire - Fri Apr 25, 4:27PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company"
(NASDAQ: GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Lieff Cabraser Reminds Geron Corporation Investors of Upcoming Deadline in Class Action Litigation - GERN
Business Wire - Thu Apr 24, 8:01AM CDT
Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 13, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired the securities of Geron Corporation ("Geron" or the "Company"
(NasdaqGS: GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" . Geron Announces Conference Call to Discuss First Quarter 2014 Financial Results
Thomson Reuters ONE - Wed Apr 23, 3:21PM CDT
Menlo Park, Calif., April 23, 2014 - Geron Corporation (Nasdaq: GERN) will announce its financial results for the first quarter ended March 31, 2014, on Thursday, May 1, 2014, after the market close. Geron's management will also host a conference call for analysts and investors on Thursday, May 1, 2014, at 4:30 p.m. Eastern Time to discuss the company's first quarter results and recent events.
2 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Apr 23, 6:45AM CDT
Keep these under-$10 biotech stocks on your trading radar.
Prana Biotechnology Stock Hits New Low
ACCESSWIRE - Wed Apr 16, 9:47AM CDT
Prana Biotechnology (NASDAQ
RAN) share value has been tumbling over the last month, closing at $1.74 Apr. 15, down 15 cents from the previous day's close of $1.89. 5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Global Polycythemia Vera Therapeutic Pipeline Review 2014 - Analysis of 6 Companies and 7 Drug Profiles
M2 - Tue Apr 15, 6:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fn53p5/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Polycythemia Vera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycythemia Vera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycythemia Vera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycythemia Vera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Polycythemia Vera - Companies Involved in Therapeutics Development - Eli Lilly and Company - Incyte Corporation - Geron Corporation - Italfarmaco S.p.A. - PharmaEssentia Corporation - miRagen Therapeutics, Inc. Drug Profiles - ruxolitinib phosphate - peginterferon alfa-2b - imetelstat sodium - givinostat - gandotinib - MGN-4893 - Small Molecules to Inhibit JAK for Oncology and Hematological Disorders For more information visit http://www.researchandmarkets.com/research/fn...hemia_vera
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 14, 12:45PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Geron Corporation of Class Action Lawsuit and Upcoming Deadline -- GERN
GlobeNewswire - Fri Apr 11, 3:12PM CDT
Pomerantz LLP announces the filing of a class action lawsuit against Geron Corporation ("Geron" or the "Company"
(Nasdaq:GERN) and certain of its officers. The class action, filed in United States District Court, Northern District of California and docketed under 14-cv-01424, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Geron between June 16, 2013 and March 11, 2014, both dates inclusive (the "Class Period" . This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against Geron Corporation
Business Wire - Thu Apr 10, 9:32AM CDT
Law Offices of Howard G. Smith reminds investors that all purchasers of the securities of Geron Corporation ("Geron" or the "Company"
(NASDAQ:GERN) between June 16, 2013 and March 11, 2014, inclusive (the "Class Period" , have until May 13, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit. Hagens Berman Reminds Investors of May 13, 2014, Lead Plaintiff Deadline in Geron Securities Class Action
Business Wire - Wed Apr 09, 12:38PM CDT
Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) ("Geron" or "the Company"
for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the May 13, 2014 lead plaintiff deadline. Investors who have suffered significant financial losses, and who want to discuss their options, can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing Geron@hbsslaw.com or by calling 510-725-3000. 
